Drugs / Hepatitis B Immunoglobulin
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07328711 | Jan 2026 → Dec 2028 expected | chronic hepatitis B virus infection | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00507689 | Sep 2007 → May 2011 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00240526 | Oct 2003 → Mar 2010 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02312531 | May 2012 → May 2014 | hepatitis B virus infection | Xi'an Jiaotong University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hepatitis B Immunoglobulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07328711 ↗ |
| Known as | HBIg | “Hepatitis B Immunoglobulin (HBIg)” NCT07328711 ↗ |
| Modality | Protein / enzyme biologic | “hepatitis B immunoglobulins (HBIg)” NCT00240526 ↗ |
| Route | Intramuscular | “HBIg was administered either intravenously or by intramuscular injection” NCT00507689 ↗ |
| Route | Intravenous | “HBIg was administered either intravenously or by intramuscular injection” NCT00507689 ↗ |